Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients

Schöllkopf, Claudia, Kjeldsen, Lars, Bjerrum, Ole Weiss, Mourits-Andersen, Hans Torben, Nielsen, Johan Lanng, Christensen, Bjarne Egelund, Jensen, Bjarne Anker, Pedersen, Bjarne Bach, Taaning, Ellen Birkerod, Klausen, Tobias Wirenfeldt, Birgens, Henrik·2006·Leukemia & Lymphoma

Abstract

Chronic cold agglutinin disease (CAD) is an acquired autoimmune hemolytic anemia. Previous therapeutic modalities, including alkylating cytostatics, interferon and prednisolone, have been disappointing. However, several case reports and small-scaled studies have demonstrated promising results after treatment with rituximab. We performed a phase II multicentre trial to investigate the effect of rituximab in CAD, including 20 patients studied from October 2002 until April 2003. Thirteen patients had idiopathic CAD and seven patients had CAD associated with a malignant B-cell lymphoproliferative disease. Rituximab was given in doses of 375 mg/m(2) at days 1, 8, 15 and 22. Sixteen patients were followed up for at least 48 weeks. Four patients were excluded after 8, 16, 23 and 28 weeks for reasons unrelated to CAD. Nine patients (45%) responded to the treatment, one with complete response (CR), and eight with partial response. Eight patients relapsed, one patient was still in remission at the end of follow-up. There were no serious rituximab-related side-effects. Our study confirms previous findings of a favourable effect of rituximab in patients with CAD. However, few patients will obtain CR and, in most patients, the effect will be transient.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/10428190500286481

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 175

Metadata

Authors
Schöllkopf, C., Kjeldsen, L., Bjerrum, O. W., Mourits-Andersen, H. T., Nielsen, J. L., Christensen, B. E., Jensen, B. A., Pedersen, B. B., Taaning, E. B., Klausen, T. W., & Birgens, H.
Venue
Leukemia & Lymphoma
Published
2006-01
Volume
47
Issue
2
Pages
253-260
ISSN
  • 1026-8022 (ISSN-L)
  • 1042-8194
  • 1029-2403
OpenAlex
W1975338840
Cited by
175
References
2
FWCI
4.64
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. https://app.cochat.ai/papers/10.1080/10428190500286481
The paper
Schöllkopf, C., Kjeldsen, L., Bjerrum, O. W., Mourits-Andersen, H. T., Nielsen, J. L., Christensen, B. E., Jensen, B. A., Pedersen, B. B., Taaning, E. B., Klausen, T. W., & Birgens, H. (2006). Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leukemia & Lymphoma. https://doi.org/10.1080/10428190500286481

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.